摘要
目的探讨新型冠状病毒肺炎抗病毒药物的相互作用。方法检索抗病毒药物α-干扰素、洛匹那韦/利托那韦、利巴韦林、磷酸氯喹、阿比多尔的药物相互作用文献,整理并分析这些药物的相互作用。结果与结论上述抗病毒药物尤其是洛匹那韦/利托那韦、磷酸氯喹和许多药物之间存在明确的相互作用,主要影响途径是抑制或诱导药物代谢酶,导致底物血药浓度变化。药物的相互作用会影响药物疗效,甚至造成不良反应,临床应用中应重视并注意避免联用或调整药物剂量。
Objective To investigate the drug-drug interactions of antiviral drugs for coronavirus disease 2019.Methods The literature on the drug-drug interactions of antiviral drugs:interferon-α,lopinavir/ritonavir,ribavirin,chloroquine,and abidor was searched,and the drug-drug interactions of these drugs were collated and analyzed.Results and Conclusion There was a clear interaction between these antiviral drugs and many drugs,especially lopinavir/ritonavir and chloroquine,which was mainly affected by interfering with drug metabolic enzymes.The drug interactions of these antiviral drugs are clear,the drug-drug interactions will affect the efficacy of drugs,or even cause adverse reactions.Therefore,we should pay attention to these drug-drug interactions,avoid drug combinations or adjust dosage appropriately.
作者
陈昭阳
骆旭东
何治尧
柏杨
徐珽
苏娜
CHEN Zhaoyang;LUO Xudong;HE Zhiyao;BAI Yang;XU Ting;SU Na(Department of Clinical Pharmacy,West China Hospital,Sichuan University,Chengdu,Sichuan,China 610041;State Key Laboratory of Biotherapy,Sichuan University,Chengdu,Sichuan,China 610041;Department of Clinical Pharmacy and Pharmaceutical Administration,West China School of Pharmacy,Sichuan University,Chengdu,Sichuan,China 610041)
出处
《中国药业》
CAS
2020年第12期18-23,共6页
China Pharmaceuticals
基金
四川省软科学研究计划项目[2018ZR0212]。
